Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A novel T-cell vaccine strategy designed to deal with the enormity of HIV-1 variation is described and tested for the first time in macaques to inform and complement approaching clinical trials. T-cell immunogen HIVconsv, which directs vaccine-induced responses to the most conserved regions of the HIV-1, proteome and thus both targets diverse clades in the population and reduces the chance of escape in infected individuals, was delivered using six different vaccine modalities: plasmid DNA (D), attenuated human (A) and chimpanzee (C) adenoviruses, modified vaccinia virus Ankara (M), synthetic long peptides, and Semliki Forest virus replicons. We confirmed that the initial DDDAM regimen, which mimics one of the clinical schedules (DDDCM), is highly immunogenic in macaques. Furthermore, adjuvanted synthetic long peptides divided into sub-pools and delivered into anatomically separate sites induced T-cell responses that were markedly broader than those elicited by traditional single-open-reading-frame genetic vaccines and increased by 30% the overall response magnitude compared with DDDAM. Thus, by improving both the HIV-1-derived immunogen and vector regimen/delivery, this approach could induce stronger, broader, and theoretically more protective T-cell responses than vaccines previously used in humans.

Original publication

DOI

10.1002/eji.201040344

Type

Journal article

Journal

Eur J Immunol

Publication Date

07/2010

Volume

40

Pages

1973 - 1984

Keywords

AIDS Vaccines, Animals, Cell Proliferation, Conserved Sequence, Drug Delivery Systems, Epitope Mapping, Epitopes, T-Lymphocyte, Genetic Vectors, HIV Antigens, HIV-1, Humans, Immunization, Lymphocyte Activation, Macaca mulatta, Peptide Fragments, Peptide Library, T-Cell Antigen Receptor Specificity, T-Lymphocytes